ABSTRACT
OBJECTIVE: To find out the patent situation of duloxetine and provide references for domestic pharmaceutical companies to establish appropriate R&D strategies.
ABSTRACT
Introducción: los síntomas vasomotores se reportan con frecuencia durante la peri y posmenopausia, y afectan de forma importante la calidad de vida de las mujeres que los sufren. Los estrógenos continúan siendo el tratamiento de elección para estos síntomas, sin embargo, en algunas mujeres este tipo de tratamiento está contraindicado, mientras que otras mujeres simplemente no aceptan usarlo. El objetivo del presente trabajo es hacer una revisión de estudios clínicos que evalúan la eficacia de los antidepresivos en el tratamiento de los síntomas vasomotores. Materiales y métodos: se realizó una revisión en las bases de datos Medline vía PubMed, EBSCO y Ovid. Se incluyeron artículos, publicados entre 2002 y 2011, de ensayos clínicos aleatorizados, meta-análisis y revisiones sistemáticas que evaluaron la eficacia de fármacos antidepresivos en el tratamiento de síntomas vasomotores. Resultados: se observa que los antidepresivos ayudan a aliviar los síntomas vasomotores e inciden favorablemente en los síntomas neuropsiquiátricos propios del climaterio, tales como la irritabilidad, las alteraciones del sueño y la labilidad emocional. Los estudios en relación a la fisiopatología de los bochornos soportan la hipótesis de que los antidepresivos pueden ser útiles para su tratamiento. Dentro del grupo de medicamentos antidepresivos existe evidencia para el uso de sertralina, fluoxetina, citalopram y venlafaxina. Conclusión: el uso de antidepresivos puede ser útil en el tratamiento de los síntomas vasomotores relacionados con la menopausia. Debemos considerar aquellos que tengan un perfil farmacológico noradrenérgico y serotoninérgico...
Introduction: vasomotor symptoms are frequently reported during the peri and postmenopausal periods and drastically affect the quality of life of those women who suffer them. Estrogens continue being the treatment of choice for such symptoms; however, this type of treatment is contraindicated in some women, whilst other women simply refuse to use them. The present work was aimed at reviewing clinical studies which have evaluated antidepressant drugs effectiveness regarding the treatment of vasomotor symptoms. Materials and methods: Medline / PubMed, EBSCO, and Ovid databases were reviewed. Articles published between 2002 and 2011 were included, as were randomized clinical assays, metaanalyses and systematic reviews which evaluated antidepressant drugs effectiveness in treating vasomotor symptoms. Results: it was observed that antidepressants helped to alleviate vasomotor symptoms and had a favorable effect on neuropsychiatric symptoms related to the menopause, such as irritability, alterations in sleeping patterns and emotional ability. Studies regarding hot flushes physiopathology supported the hypothesis that antidepressants could be useful for treating them. Evidence regarding the group of antidepressant medicines suggested using sertraline, fluoxetine, citalopram and venlafaxine. Conclusion: antidepressant drugs could be useful in treating menopause-related vasomotor symptoms; those having a noradrenergic and serotoninergic pharmacological profile should be considered...
Subject(s)
Female , Middle Aged , Climacteric , Hot Flashes , TherapeuticsABSTRACT
While in the past the almost sole availability of tricyclic antidepressants had limited antidepressant drug selection, newer drugs such as selective serotonin reuptake inhibitors, bupropion, mirtazapine and venlafaxine have vastly simplified treating depression in patients with medical illness. Appropriate selection of an antidepressant agent in medically ill patients requires a careful risk-benefit assessment of the antidepressant treatment considering the pharmacokinetic and pharmacodynamic properties of drugs, potential for drug interaction, the patient's general medical conditions, and primary symptoms of the patient's depression. The effective and safe approach to antidepressant treatment is to reduce initial dosage, to titrate upward more slowly, and to monitor closely adverse effects in patients with medical illness.
Subject(s)
Humans , Antidepressive Agents, Tricyclic , Bupropion , Depression , Drug Interactions , Risk Assessment , Selective Serotonin Reuptake Inhibitors , Venlafaxine HydrochlorideABSTRACT
Dilated cardiomyopathy is a primary myocardial disease characterized by ventricular dilatation and impaired ventricular contractility. The etiology of dilated cardiomyopathy has not been known yet, but toxin such as alcohol, thiamine deficiency, endocrine disorder, viral or bacterial infection, hereditary disorder, and muscular dystrophy may be related to dilated cardiomyopathy. Cocaine abuse and anticancer drugs (especially doxorubicin) were reported as the causes of drugs of dilated cardiomyopathy also. Recently we experinced a case of dilated cardiomyopathy in 30 years old man who developed dilated cardiomyopathy on chronic clomipramine (one of trcyclic antidepressant drugs) treatment for a obsessive-compulsive disorder. He became asymptomatic and normalization of left ventricular diameters and function was evidenced echocardiographically after withdrawal of the drug. The possible association of cardiomyopathy and tricyclic antidepressant drugs and possibility of functional improvement after tricyclic antidepressant drugs withdrawal should be kept in mind.